Label-free drug response evaluation of human derived tumor spheroids using three-dimensional dynamic optical coherence tomography.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 09 2023
16 09 2023
Historique:
received:
13
04
2023
accepted:
31
08
2023
medline:
18
9
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
epublish
Résumé
This study aims at demonstrating label-free drug-response-patterns assessment of different tumor spheroids and drug types by dynamic optical coherence tomography (D-OCT). The study involved human breast cancer (MCF-7) and colon cancer (HT-29) spheroids. The MCF-7 and HT-29 spheroids were treated with paclitaxel (Taxol; PTX) and the active metabolite of irinotecan SN-38, respectively. The drugs were applied with 0 (control), 0.1, 1, and 10 μM concentrations and the treatment durations were 1, 3, and 6 days. A swept-source OCT microscope equipped with a repeated raster scanning protocol was used to scan the spheroids. Logarithmic intensity variance (LIV) and late OCT correlation decay speed (OCDS[Formula: see text]) algorithms were used to visualize the tumor spheroid dynamics. LIV and OCDS[Formula: see text] images visualized different response patterns of the two types of spheroids. In addition, spheroid morphology, LIV, and OCDS[Formula: see text] quantification showed different time-courses among the spheroid and drug types. These results may indicate different action mechanisms of the drugs. The results showed the feasibility of D-OCT for the evaluation of drug response patterns of different cell spheroids and drug types and suggest that D-OCT can perform anti-cancer drug testing.
Identifiants
pubmed: 37717067
doi: 10.1038/s41598-023-41846-3
pii: 10.1038/s41598-023-41846-3
pmc: PMC10505213
doi:
Substances chimiques
Irinotecan
7673326042
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15377Informations de copyright
© 2023. Springer Nature Limited.
Références
Front Oncol. 2017 Dec 11;7:293
pubmed: 29322028
Eur J Pharmacol. 2016 Jun 15;781:173-80
pubmed: 27083550
PLoS One. 2017 Sep 6;12(9):e0183074
pubmed: 28877221
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10166-10173
pubmed: 16801540
Opt Express. 2019 Jul 8;27(14):19562-19572
pubmed: 31503714
Light Sci Appl. 2020 Aug 17;9:140
pubmed: 32864115
Front Oncol. 2021 Jun 24;11:682968
pubmed: 34249731
Sci Rep. 2019 Feb 5;9(1):1407
pubmed: 30723234
Onco Targets Ther. 2016 Nov 22;9:7207-7218
pubmed: 27920558
Optica. 2015 Oct 20;2(10):877-885
pubmed: 26973862
Cell Tissue Res. 2013 Apr;352(1):161-77
pubmed: 23443300
Neurophotonics. 2020 Jan;7(1):015013
pubmed: 32206680
Biomed Opt Express. 2020 Apr 28;11(5):2768-2778
pubmed: 32499959
Cancer Res. 1991 Aug 15;51(16):4187-91
pubmed: 1651156
Curr Biol. 1998 May 21;8(11):R394-7
pubmed: 9635187
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3294-8
pubmed: 8475071
Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:4177-4180
pubmed: 28269203
Biomed Opt Express. 2021 Oct 12;12(11):6844-6863
pubmed: 34858684
Biomed Opt Express. 2021 May 13;12(6):3352-3371
pubmed: 34221665
Biomed Opt Express. 2021 Jun 03;12(7):3789-3805
pubmed: 34457380
Opt Lett. 2020 Sep 1;45(17):4766-4769
pubmed: 32870852
Biomed Opt Express. 2020 Oct 08;11(11):6231-6248
pubmed: 33282486
Commun Biol. 2022 Jun 10;5(1):575
pubmed: 35688936
Pharmaceutics. 2021 Apr 14;13(4):
pubmed: 33919902
Biomed Opt Express. 2022 May 05;13(6):3211-3223
pubmed: 35781952
Biomed Opt Express. 2016 Mar 24;7(4):1511-24
pubmed: 27446672
J Vis Exp. 2022 Jun 21;(184):
pubmed: 35815980
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Cell Biol. 2008 Nov 17;183(4):583-7
pubmed: 19001127
Biomed Opt Express. 2021 Sep 07;12(10):6024-6039
pubmed: 34745719
Cell Calcium. 2012 Jun;51(6):459-69
pubmed: 22579052
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
BMC Biol. 2012 Mar 22;10:29
pubmed: 22439642
Biosensors (Basel). 2021 Nov 11;11(11):
pubmed: 34821661
Biochem Biophys Res Commun. 2013 May 17;434(4):753-9
pubmed: 23583407
Am J Pathol. 1995 Jan;146(1):3-15
pubmed: 7856735
Cells. 2019 Apr 18;8(4):
pubmed: 31003495
Adv Drug Deliv Rev. 2018 Feb 1;125:3-20
pubmed: 29326054
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
Biomed Opt Express. 2016 Oct 07;7(11):4501-4513
pubmed: 27895991
Cancer Drug Resist. 2021 Nov 2;4(4):946-964
pubmed: 35582377
Cancer Res. 1989 Sep 15;49(18):5077-82
pubmed: 2548710
Oncotarget. 2017 Aug 24;8(56):95316-95331
pubmed: 29221130
J Biomol Screen. 2006 Dec;11(8):922-32
pubmed: 16973921
Cancer Res. 2017 Nov 1;77(21):6011-6020
pubmed: 28904062
Eur Biophys J. 2008 Sep;37(7):1271-8
pubmed: 18404264
Nat Rev Mol Cell Biol. 2021 Dec;22(12):777-795
pubmed: 34408299
Assay Drug Dev Technol. 2019 Apr;17(3):140-149
pubmed: 30958703
Br J Pharmacol. 1993 Oct;110(2):507-17
pubmed: 8242225
Biomed Opt Express. 2017 Feb 01;8(3):1290-1305
pubmed: 28663829
Transl Vis Sci Technol. 2022 May 2;11(5):28
pubmed: 35622381
Essays Biochem. 2018 Dec 7;62(6):725-735
pubmed: 30287587
Cancer Res. 1986 Oct;46(10):5320-9
pubmed: 3756881
Cell. 2003 Feb 21;112(4):467-80
pubmed: 12600311
Cancer. 2021 Aug 15;127(16):3029-3030
pubmed: 34086348
Int J Oncol. 2016 Aug;49(2):753-62
pubmed: 27278553
Sci Rep. 2019 May 8;9(1):7103
pubmed: 31068603
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Annu Rev Cell Dev Biol. 2002;18:193-219
pubmed: 12142285
Cold Spring Harb Perspect Biol. 2015 Dec 01;7(12):
pubmed: 26626938
Cancer Cell Int. 2021 Mar 4;21(1):152
pubmed: 33663530
Oncol Rep. 2008 Jun;19(6):1493-8
pubmed: 18497955